Pfizer: FDA grants priority review to glasdegib
(CercleFinance.com) - US health regulators have granted a priority review for Pfizer's leukemia drug glasdegib, speeding up the experimental treatment's route to the market.
The US Food and Drug Administration has accepted the company's new drug application and granted priority review designation for patients with previously untreated acute myeloid leukemia (AML) in combination with chemotherapy, the drugmaker said.
The FDA is now set to make a decision by December 2018.
An oral, once-daily therapy, Glasdegib disrupts the Hedgehog pathway, thought to play a role in the development of several cancers such as solid tumors and hematologic malignancies.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
The US Food and Drug Administration has accepted the company's new drug application and granted priority review designation for patients with previously untreated acute myeloid leukemia (AML) in combination with chemotherapy, the drugmaker said.
The FDA is now set to make a decision by December 2018.
An oral, once-daily therapy, Glasdegib disrupts the Hedgehog pathway, thought to play a role in the development of several cancers such as solid tumors and hematologic malignancies.
Copyright (c) 2018 CercleFinance.com. All rights reserved.